J-Pharma Co.,Ltd. (520A.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

JPY 6.28B

MomentumView details →

1D Return

−10.74%

YTD Return

—

RSI (14)

68.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

JPY 6.28B

RSI (14)

68.7

MomentumView details →

1D Return

−10.74%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

J-Pharma announced a transition to an executive officer system to strengthen management and business execution, with Shinya Hirata newly appointed as executive officer in charge of clinical development and regulatory affairs.3d ago

The USFDA completed an inspection of Aurolife Pharma's Raleigh Plant in North Carolina, USA, from 24 March 2025 to 10 April 2025, issued a Form 483 with 11 observations, and subsequently closed the inspection with a Voluntary Action Indicated (VAI) classification.19d ago

Similar companies

Noile-Immune Biotech Inc.4893.T PRISM BioLab Co.,LTD206A.T BrightPath Biotherapeutics Co.,Ltd.4594.T CellSource Co.,Ltd.4880.T Solasia Pharma K.K.4597.T NIPPON CHEMIPHAR CO.,LTD.4539.T Find similar companies →

Latest newsMore news →

J-Pharma announced a transition to an executive officer system to strengthen management and business execution, with Shinya Hirata newly appointed as executive officer in charge of clinical development and regulatory affairs.3d ago The USFDA completed an inspection of Aurolife Pharma's Raleigh Plant in North Carolina, USA, from 24 March 2025 to 10 April 2025, issued a Form 483 with 11 observations, and subsequently closed the inspection with a Voluntary Action Indicated (VAI) classification.19d ago